Publikationen, an denen er mitarbeitet María Isabel Loza García (46)

2020

  1. Essential role of the C148–C227 disulphide bridge in the human 5-HT2A homodimeric receptor

    Biochemical Pharmacology, Vol. 177

2017

  1. Effect of Nitrogen Atom Substitution in A3 Adenosine Receptor Binding: N-(4,6-Diarylpyridin-2-yl)acetamides as Potent and Selective Antagonists

    Journal of Medicinal Chemistry, Vol. 60, Núm. 17, pp. 7502-7511

  2. Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates

    Journal of Medicinal Chemistry, Vol. 60, Núm. 8, pp. 3372-3382

  3. Exploring the influence of the substituent at position 4 in a series of 3,4-dihydropyrimidin-2(1H)-one A2B adenosine receptor antagonists

    Chemistry of Heterocyclic Compounds, Vol. 53, Núm. 3, pp. 316-322

  4. Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease

    Future Medicinal Chemistry, Vol. 9, Núm. 8, pp. 731-748

  5. Serotonin 2A receptor disulfide bridge integrity is crucial for ligand binding to different signalling states but not for its homodimerization

    European Journal of Pharmacology, Vol. 815, pp. 138-146

  6. Serotonin-2A homodimers are needed for signalling via both phospholipase A2 and phospholipase C in transfected CHO cells

    European Journal of Pharmacology, Vol. 800, pp. 63-69

  7. Targeting PDE10A GAF domain with small molecules: A way for allosteric modulation with anti-inflammatory effects

    Molecules, Vol. 22, Núm. 9

2016

  1. Development of a Multiplex Assay for Studying Functional Selectivity of Human Serotonin 5-HT2A Receptors and Identification of Active Compounds by High-Throughput Screening

    Journal of Biomolecular Screening, Vol. 21, Núm. 8, pp. 816-823

2015

  1. Reelin influences the expression and function of dopamine D2 and serotonin 5-HT2A receptors: A comparative study

    Neuroscience, Vol. 290, pp. 165-174

2014

  1. Modulation of cAMP-specific PDE without emetogenic activity: New sulfide-like PDE7 inhibitors

    Journal of Medicinal Chemistry, Vol. 57, Núm. 20, pp. 8590-8607

2013

  1. Discovery of 3,4-dihydropyrimidin-2(1 H)-ones as a novel class of potent and selective A2B adenosine receptor antagonists

    ACS Medicinal Chemistry Letters, Vol. 4, Núm. 11, pp. 1031-1036

  2. Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold

    European Journal of Medicinal Chemistry, Vol. 59, pp. 235-242

  3. The arylpiperazine derivatives N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide and N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide exert a long-lasting inhibition of human serotonin 5-HT7 receptor binding and cAMP signaling

    Pharmacology Research and Perspectives, Vol. 1, Núm. 2

  4. Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities

    European Journal of Medicinal Chemistry, Vol. 70, pp. 781-788

2012

  1. Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds

    Journal of Medicinal Chemistry, Vol. 55, Núm. 7, pp. 3274-3284

  2. Identification in Silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice

    ACS Chemical Neuroscience, Vol. 3, Núm. 10, pp. 793-803

  3. Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model

    European Journal of Medicinal Chemistry, Vol. 47, Núm. 1, pp. 175-185

2011

  1. Discovery of LAS101057: A potent, selective, and orally efficacious A 2B Adenosine Receptor Antagonist

    ACS Medicinal Chemistry Letters, Vol. 2, Núm. 3, pp. 213-218

  2. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists

    Journal of Medicinal Chemistry, Vol. 54, Núm. 2, pp. 457-471